Chris Leibman is the Head of Value, Access, Public Policy and Government Affairs at Biogen, where he leads the global value demonstration, patient access and pricing strategy development and execution across the Biogen portfolio, as well as, the Public Policy and Government Affairs organization. Prior to this role Chris lived in Zug, Switzerland where he led market Access and pricing at Biogen for Europe and Canada.
Mr. Leibman joined Biogen in 2014 from Janssen Pharmaceuticals (J&J), where he served as head of Market Access and Policy: Neuroscience and led the team responsible for the development and execution of market access strategies and value evidence generation across the Neuroscience franchise. Prior to this, first with Élan Pharmaceuticals and then with Janssen AI following their program acquisition, Chris led the market access launch readiness activities across the Alzheimer Immunotherapy Program in partnership with Pfizer.
Mr. Leibman has published and presented extensively on the benefits and costs of prescription drugs in Alzheimer’s disease, value frameworks in healthcare, and sustainable pricing in drug development. He brings two decades of diverse experiences in biopharmaceutical development, value demonstration, access, and working across multi-company alliances.
Mr. Leibman holds a B.S. degree in Biology, from the University of Illinois at Urbana-Champaign and Doctor of Pharmacy from the University of Illinois at Chicago. Following his pharmacy degree, he completed a post-doc fellowship in health economics with GlaxoWellcome and earned a M.S. degree with focus in Pharmacoeconomics and Health Policy from the Ohio State University.